

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Currently amended)** A prognostic method for determining whether a subject is at risk for developing spontaneous abortion comprising detecting the presence or level of mRNA ~~or polypeptide~~ of one or more of:

a) an adhesion molecule,

b) an inflammatory cytokine selected from the group consisting of IL-2, IL-12, IL-11, IL-1 β , TGF, RANTES and IL-6, or

c) an immune cell surface molecule

in a biological sample obtained from said subject, or isolate of said sample, and determining if the presence or level of said mRNA is abnormal, wherein an abnormal presence or level of said mRNA indicates ~~thereby determining whether~~ the subject is at risk for developing spontaneous abortion.

2. **(Original)** The method of claim 1, wherein the adhesion molecule is selected from the group consisting of VCAM-1, P-selectin, and E-selectin.

3. **(Currently amended)** The method of claim 1 ~~4~~ 16, wherein the inflammatory cytokine is selected from the group consisting of IL-2, ~~IL-10~~, IL-12, IL-11, TNF α , IL-1 β , TGF, RANTES, IL-6, and IFN- γ .

4. **(Currently amended)** The method of claim 1, wherein the immune cell surface molecule is selected from the group consisting of B7.1 (CD80), B7.2 (CD86), CD4, CD8, GL50, and ICOS }.

5. **(Currently amended)** A diagnostic method for determining whether a subject is ~~suffering from~~ undergoing a spontaneous abortion comprising detecting the presence or level of mRNA ~~or polypeptide~~ of one or more of:

a) an adhesion molecule,

b) an inflammatory cytokine selected from the group consisting of IL-2, IL-12, IL-11, IL-1 β , TGF, RANTES and IL-6, or

c) an immune cell surface molecule

in a biological sample obtained from said subject, or isolate of said sample, and determining if the presence or level of said mRNA is abnormal, wherein an abnormal presence or level of said mRNA indicates ~~thereby determining whether~~ the subject is having a spontaneous abortion.

6. **(Original)** The method of claim 5, wherein the adhesion molecule is selected from the group consisting of VCAM-1, P-selectin, and E-selectin.

7. **(Currently amended)** The method of claim ~~5~~ 17, wherein the inflammatory cytokine is selected from the group consisting of IL-2, ~~IL-10~~, IL-12, IL-11, TNF α , IL-1 β , TGF, RANTES, IL-6, and IFN- γ .

8. **(Currently amended)** The method of claim 5, wherein the immune cell surface molecule is selected from the group consisting of B7.1 (CD80), B7.2 (CD86), CD4, CD8, GL50, and ICOS }.

9-12. **(Canceled)**

13. **(Currently amended)** The methods of ~~any of claims 1, 5, or 9~~ claim 1 or 5, further comprising comparing the level of mRNA ~~or polypeptide~~ of one or more of:

a) an adhesion molecule,

b) an inflammatory cytokine selected from the group consisting of IL-2, IL-12, IL-11, IL-1 β , TGF, RANTES and IL-6, or

c) an immune cell surface molecule ~~moleleule~~

in the biological sample obtained from said subject, or isolate of said sample, to the level of mRNA ~~or polypeptide~~ of one or more of:

a) an adhesion molecule,

b) an inflammatory cytokine selected from the group consisting of IL-2, IL-12, IL-11, IL-1 β , TGF, RANTES and IL-6, or

c) an immune cell surface molecule ~~molecule~~
~~in an appropriate control~~ a biological sample, or isolate of said sample, from one or more subjects who have had normal pregnancies.

14. **(Currently amended)** The methods of any of claims 1, 5, ~~or 9~~ 23 and 24, wherein the biological sample is selected from the group consisting of a tissue sample, a cell sample, ~~or~~ and a serum sample.

15. **(Original)** The method of claim 14, wherein the tissue sample is selected from the group consisting of a chorionic villus sample and a placental sample.

16. **(New)** A prognostic method for determining whether a subject is at risk for developing spontaneous abortion comprising:

detecting the presence or level of mRNA of one or more of an adhesion molecule or an immune cell surface molecule in a biological sample obtained from said subject, or isolate of said sample;

detecting the presence or level of mRNA of one or more inflammatory cytokines in a biological sample obtained from said subject, or isolate of said sample; and

determining if the presence or level of said mRNAs is abnormal, wherein an abnormal presence or level of said mRNAs indicates the subject is at risk for developing spontaneous abortion.

17. **(New)** A prognostic method for determining whether a subject is undergoing spontaneous abortion comprising:

detecting the presence or level of mRNA of one or more of an adhesion molecule or an immune cell surface molecule in a biological sample obtained from said subject, or isolate of said sample;

detecting the presence or level of mRNA of one or more inflammatory cytokines in a biological sample obtained from said subject, or isolate of said sample; and

determining if the presence or level of said mRNAs is abnormal, wherein an abnormal presence or level of said mRNAs indicates the subject is at risk for developing spontaneous abortion.

18. **(New)** The method of claim 16 or 17, wherein the adhesion molecule is selected from the group consisting of VCAM-1, P-selectin, and E-selectin.

19. **(New)** The method of claim 16 or 17, wherein the immune cell surface molecule is selected from the group consisting of B7.1 (CD80), B7.2 (CD86), CD4, CD8, GL50, and ICOS.

20. **(New)** The method of claim 16 or 17, further comprising:
comparing the level of mRNA of one or more of an adhesion molecule or an immune cell surface molecule in a biological sample obtained from said subject, or isolate of said sample, to the level of mRNA of one or more of an adhesion molecule or an immune cell surface molecule in a biological sample obtained from one or more subjects who have had normal pregnancies;
comparing the level of mRNA of one or more inflammatory cytokines in a biological sample obtained from said subject, or isolate of said sample, to the level of mRNA of one or more inflammatory cytokines in a biological sample obtained from one or more subjects who have had normal pregnancies.

21. **(New)** The method of claim 13 or 20, wherein the mRNA level of VCAM-1 is increased.

22. **(New)** The method of claim 13 or 20, wherein the mRNA level of P-selectin is increased.

23. **(New)** The method of claim 13 or 20, wherein the mRNA level of E-selectin is decreased.

24. **(New)** The method of claim 13 or 20, wherein the mRNA level of the inflammatory cytokine is increased.

25. **(New)** The method of claim 13 or 20, wherein the mRNA level of the immune cell surface molecule is increased.

26. **(New)** The method of any one of claims 22, 23, 24 and 25, wherein the mRNA level is increased by 50% or greater.

27. **(New)** The method of claim 23, wherein the mRNA level is decreased by 50% or greater.